Fig. 4
From: Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells
Synergistic effect of MS023 and BMN-673 is dependent on MTAP deficiency in A549 cells. a Immunoblotting of A549 cells infected with the empty lentivector (pLoc) or pLoc-MTAP. Clones #1 and #2 show the re-expression of MTAP using anti-MTAP antibodies. Antibodies against β-actin were used to show equivalent loading. The molecular mass markers are shown in kDa. b Same as panel A except the cellular lysates were immunoblotted with anti-SDMA and β-actin antibodies as indicated. c MTT cell viability assays were performed with A549 (PLOC) and A549 (MTAP #1, #2) treated with a range of MS023 concentrations. Dotted vertical lines represent IC50 values (n = 3). (*p < 0.05, two-way ANOVA) indicates a statistical difference PLOC and MTAP clones. d Cell viability curves as determined by MTT assay of the A549 clones treated with a range of BMN-673 in combination 2 µM MS023 (n = 4). **(p < 0.01, two-way ANOVA) indicates a statistical difference PLOC and MTAP clones